In recent years there has been significant progress in the development of attenuated Salmonella enterica serovar Typhi strains as candidate typhoid fever vaccines. In clinical trials these vaccines have been shown to be well tolerated and immunogenic. For example, the attenuated S. enterica var. Typhi strains CVD 908-htrA (aroC aroD htrA), Ty800 (phoP phoQ) and M4073 (cya crp cdt) are all promising candidate typhoid vaccines. In addition, clinical trials have demonstrated that S. enterica var. Typhi vaccines expressing heterologous antigens, such as the tetanus toxin fragment C, can induce immunity to the expressed antigens in human volunteers. In many cases, the problems associated with expression of antigens in Salmonella have been successfully addressed and the future of Salmonella vaccine development is very promising.
Introduction
Typhoid fever is a public health problem of which there are an estimated 33 million cases and a resulting 500 000 deaths each year worldwide [1] . Caused by the Gram-negative bacterium Salmonella enterica serovar Typhi (previously known as Salmonella typhi), typhoid fever is endemic in many developing countries including areas of Africa, Asia and South America [1] . Particularly at risk of contracting the disease are children in endemic areas, and also travellers and microbiological laboratory technicians. These populations would bene¢t from the use of an e¡ec-tive typhoid fever vaccine.
Previously, inactivated whole-cell vaccines given parentally have been used to provide protection against typhoid fever. However, due to the high incidence of associated adverse systemic and local reactions, they are generally considered to be unsuitable for use as public health vaccines [1] . Thus, two vaccines have been developed during the past 15 years and are licensed for use against typhoid fever. First, a parental capsular polysaccharide vaccine based on the S. enterica var. Typhi Vi antigen [2] . Second, a live attenuated oral vaccine containing S. enterica var. Typhi strain Ty21a [3] . Both of these vaccines have been used successfully to immunise against typhoid fever. However, as a result of their shortfalls, such as the unknown basis of attenuation in Ty21a, a number of new genetically de¢ned attenuated strains of S. enterica var. Typhi have been constructed as candidate live oral vaccines.
Over the last three decades, such attenuated Salmonella vaccine strains have also been exploited by using them to express heterologous antigens to induce immunity against a variety of pathogens. Previous reviews have considered the construction and evaluation of S. enterica var. Typhimurium strains in animal models. In this paper, we have focused on the evaluation of S. enterica var. Typhi vaccines in clinical trials. The use of Salmonella vaccines as candidate typhoid fever vaccines and as carriers of heterologous antigens will be reviewed. In addition, problems associated with their development, and solutions to these problems, which have been devised, are discussed.
Typhoid vaccines

Current typhoid vaccines
The Vi capsular polysaccharide of S. enterica var. Typhi, ¢rst identi¢ed over 60 years ago [4] , is both a virulence factor and a protective antigen [4, 5] . The Vi antigen is thought to prevent antibodies from binding to the O antigen, allowing S. enterica var. Typhi to survive in the blood, and is also associated with inhibition of complement activation and resistance to complement-mediated lysis and phagocytosis [4, 6] . Vi-speci¢c serum antibody is necessary to activate complement against S. enterica var.
Typhi. Immunisation with the capsular polysaccharide vaccine has been shown in several studies to stimulate protective antibody responses against typhoid fever and is generally considered e⁄cacious (reviewed by Hessel et al. [2] ). However, following inoculation with the vaccine some side e¡ects occur. For example, 17% of adult vaccinees and 86.7% of child vaccinees experience local pain at the injection site, although these reactions are usually transient and non-severe [2] . The vaccine is usually administered subcutaneously as a single dose of 25 Wg to individuals over 2 years of age, confers protection within 7^10 days of inoculation, and requires 3-year boosters [1, 7, 8] . New generations of typhoid vaccines being studied include parenteral Vi polysaccharide^protein conjugate vaccines which are expected to produce higher antibody titres following initial and booster immunisations than the Vi vaccine [8] .
The second licensed typhoid vaccine currently available, attenuated S. enterica var. Typhi strain Ty21a, was developed by chemical mutagenesis [3] . Other early classically attenuated Salmonella vaccines include temperature-sensitive mutants [9] and streptomycin-dependent mutants [10] . Such mutants were obtained by the identi¢cation of a particular phenotype, i.e. a reduction in virulence. Ty21a is characterised by a galE mutation [8] and an inability to synthesise the Vi capsular antigen. It was originally believed that the attenuation of Ty21a was due solely to the galE mutation, which renders the bacterium galactose epimerase-de¢cient, thus a¡ecting O antigen production. However, it has since been shown that this mutation does not account for the degree of attenuation of Ty21a, since a genetically de¢ned S. enterica var. Typhi galE and Vi-negative mutant retained some virulence when tested in human volunteers [11] . Interestingly, S. enterica var. Typhimurium with de¢ned mutations in the galE gene are attenuated and immunogenic in mice [12] . Thus, the mutations that attenuate S. enterica var. Typhi Ty21a are not fully de¢ned. In addition, a theoretical problem associated with Ty21a is reversion to virulence, although no revertants have been isolated to date [13] .
Like the Vi antigen vaccine, Ty21a has been evaluated as a typhoid vaccine in several e⁄cacy trials and shown to be safe and e¡ective [14^20]. Ty21a is only modestly immunogenic and requires three to four initial doses [16^20] . Therefore the vaccine is usually administered initially as three to four capsules containing bacteria on alternate days, and requires boosters every 5 years [8] , although a liquid formulation of the Ty21a vaccine has been developed which has been shown to further improve the protection a¡orded [19, 20] . In addition, it has been shown that Ty21a can be co-administered with the live oral cholera vaccine CVD103-HgR without a¡ecting the safety or immunogenicity of either vaccine [21, 22] . In contrast, the immunogenicity of Ty21a was decreased by the simultaneous administration of antimalarial drugs [22] . For all of the reasons highlighted above, the replacement of Ty21a as a typhoid vaccine with a more e⁄cacious and better de¢ned vaccine is desirable.
New live attenuated S. enterica serovar Typhi vaccines
As a result of the shortfalls associated with Ty21a, and with a greater understanding of the genetics of Salmonella virulence and recombinant DNA technology, a number of new genetically de¢ned attenuated strains of S. enterica var. Typhi have been developed as candidate live oral vaccines (recently reviewed by Mastroeni et al. [23] ).
Genetic and biochemical basis of attenuation
One of the most widely studied classes of attenuated Salmonella are auxotrophs. In the 1950s Bacon et al. [24] found that auxotrophic mutants of S. enterica var. Typhi, requiring p-aminobenzoic acid (PABA), had reduced virulence in mice. Salmonella synthesise PABA, along with other compounds such as 2,4-dihydroxybenzoate, from chorismate which is the ¢nal product of the shikimate pathway, also known as the aromatic (aro) biosynthetic pathway [25] . Genetically de¢ned mutants of the aroA gene, encoding 5-enolpyruvylshikimate-3-phosphate synthase, have been constructed in both S. enterica var. Typhimurium and var. Typhi. These mutants are attenuated and immunogenic in mice [26, 27] . Furthermore, oral inoculation with these mutants was shown to protect against a subsequent challenge with homologous S. enterica var. Typhimurium or var. Typhi strains [26, 27] . The mutants undergo only limited replication in vivo and are cleared from tissues after several weeks, leaving the host immune to wild-type Salmonella infection [27] . Thus the aroA mutants have good potential as live attenuated vaccines against murine and human typhoid.
As additional safety precautions from reversion of the aroA mutants to virulence, which could occur if the mutants acquired DNA from wild-type bacteria, Salmonella vaccine strains have been produced which have two or three de¢ned mutations. For example, auxotrophic mutants have been constructed with deletions in the genes involved in the purine biosynthetic pathway. Strains with a mutation in the purA gene, which encodes the enzyme adenylosuccinate synthetase, involved in the ¢rst step of the conversion of IMP to AMP in the synthesis of purines [25] , are the most widely studied. However, S. enterica var. Typhimurium strains harbouring either the purA mutation or the aroA purA double mutation have been shown to be poorly immunogenic in mice [28^31] . As alternatives to aro pur double mutants, other attenuated Salmonella double mutants have been constructed combining the aroA deletion with deletions in the shikimate pathway genes aroC (encoding chorismate synthase) or aroD (encoding 3-dehydroquinase) [32, 33] . A triple mutant containing deletions in each of the aroA, aroC and aroD mutants has also been constructed [34] . Further derivatives of aro mutants of Salmonella have been developed by deletion of the htrA gene [35, 36] . The Salmonella htrA gene is a homologue of an Escherichia coli gene encoding a heat stress protein [37] . It is thought that htrA mutants are impaired in their ability to withstand oxidative killing by macrophages [37] . De¢ned htrA mutants of Salmonella, in combination with aro mutations, make excellent oral vaccines in mice [35] and, in addition, are not increased in virulence in mice which are moderately immunode¢cient [38] .
Another well-studied group of attenuated Salmonella are mutants that have de¢ned deletions in genes involved in the regulation of Salmonella virulence. For example, mutations in genes encoding adenylate cyclase (cya) and cAMP receptor protein (crp) a¡ect the expression of genes involved in carbohydrate and amino acid metabolism and in the expression of ¢mbriae and £agella [39, 40] . S. enterica var. Typhimurium single mutants vcya or vcrp, or double mutant vcya vcrp, all show reduced virulence compared to wild-type Salmonella strains and can protect mice against oral challenge with the wild-type strain [41] . Alternatively, vaccine strains with mutations in the phoP and phoQ genes, involved in the two-component regulatory system for phosphate sensing, have been constructed and assessed as candidate vaccines against murine or human typhoid [42^44] . Other rationally mutated Salmonella strains which have been studied include those with deletions in genes involved in the biosynthesis of guanidine [45, 46] and peptidoglycan [47] , DNA recombination and repair [48] , and DNA methylation [49] .
E⁄cacy trials
Following initial studies in which S. enterica var. Typhimurium aroA were shown to be attenuated and highly immunogenic in mice [26] , and desiring well-de¢ned double mutants, Edwards and Stocker constructed an aroA purA mutant of S. enterica var. Typhi strain CDC 10-80 [50] . However, clinical trials designed to study the e⁄cacy of S. enterica var. Typhi aro pur mutants as live oral vaccines in human volunteers led to disappointing results [31] . Immunisation with S. enterica var. Typhi strains 541Ty (aroA purE, Vi-positive) or 543Ty (aroA purE, Vinegative) were well tolerated, but failed to induce su⁄cient humoral immune responses, re£ecting the poor immunogenicity of S. enterica var. Typhimurium aroA purA strains in mice [28^30] .
Since the purA mutation, alone or in combination with aroA, rendered Salmonella poorly immunogenic [28^31], double aro mutants of S. enterica var. Typhi have been constructed and evaluated [33, 34] . S. enterica var. Typhi strains CVD 906 (aroC aroD) and CVD 908 (aroC aroD) were derived from wild-type strains ISP 1820 and Ty2, respectively, and di¡ered from previous aro mutants since they contained no antibiotic resistance genes [34] . In mice, these strains were both attenuated and highly immunogenic [34] . However, in phase I clinical trials the two vaccine strains showed di¡ering reactogenicity. Adult volunteers who received 5U10 7 cfu of CVD 906 developed strong immune responses against S. enterica var. Typhi lipopolysaccharide (LPS), but showed signi¢cant adverse reactions [51] . Four volunteers developed asymptomatic vaccinaemia, two volunteers developed fever, and all volunteers excreted the Salmonella during the trial [51] . In comparison, CVD 908 was highly immunogenic, without causing febrile adverse e¡ects [52] . In volunteers who received a single dose of 5U10 7 cfu of CVD 908, 83% of vaccinees showed seroconversion to S. enterica var. Typhi LPS-speci¢c IgG and 100% of vaccinees had high levels of var. Typhi-speci¢c IgA-secreting gut lymphocytes [52] . Furthermore, vaccinees manifested lymphoproliferative responses in peripheral blood mononuclear cells [53] and developed circulating cytotoxic T lymphocytes capable of lysing var. Typhi-infected cells [54] . However, one perceived problem associated with CVD 908 was the number of silent vaccinaemias observed in healthy volunteers. Therefore CVD 908, along with CVD 906, was further modi¢ed by the introduction of a deletion into the htrA gene [36] . In a phase I clinical study, doses of 5U10
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9 cfu of CVD 906-htrA and CVD 908-htrA were generally well tolerated in volunteers, with only one case of fever and three cases of diarrhoea in 36 subjects following high doses of the vaccines [36] . Importantly, there were no cases of vaccinaemia and the vaccines were immunogenic. More recently a phase II clinical trial of S. enterica var. Typhi CVD 908-htrA was carried out [55] . Healthy adult volunteers were given either a placebo or a high dose (4.5U10 8 cfu) or a low dose (5U10 7 cfu) of CVD 908-htrA, formulated as a lyophilate. This trial di¡ered from the phase I study in which freshly harvested bacteria were used [36] . Results from the phase II study show that S. enterica var. Typhi LPS-speci¢c IgA-secreting cells were detected in 92% and 100% of low-dose and highdose vaccinees, and serum LPS-speci¢c IgG was detected in 46% and 49%, respectively [55] . A signi¢cant number of vaccinees manifested lymphoproliferative responses and interferon-Q (IFNQ) responses against S. enterica var. Typhi antigens. There were very few side e¡ects associated with the vaccine, although 8% of high-dose recipients had more frequent diarrhoea than controls (placebo recipients) [55] . S. enterica var. Typhi CVD 908-htrA is a promising typhoid vaccine candidate, which is currently in further clinical trials. In comparison, an aroA aroD htrA strain of S. enterica var. Typhi, derived from strain CDC 10-80, was found to produce adverse reactions, including bacteraemia and some cases of fever [56] .
In an interesting study, Wang et al. [57] constructed S. enterica var. Typhi strain CVD 909, consisting of CVD 908-htrA constitutively expressing the var. Typhi Vi polysaccharide capsular antigen. This strategy aimed at enhancing the protection against typhoid fever a¡orded by the CVD 908-htrA vaccine strain by stimulating Vispeci¢c antibodies. In mice, CVD 909 was more immunogenic than CVD 908-htrA in eliciting serum Vi antibodies and conferred signi¢cantly greater protection against wildtype S. enterica var. Typhi challenge following a single intranasal immunisation [57] . As a result, CVD 909 constitutes a promising candidate vaccine against typhoid fever and should now be evaluated in clinical trials.
Other attenuated S. enterica var. Typhi strains have been evaluated as candidate live typhoid vaccines in human volunteers. For example, strain Ty445, an aroA phoP phoQ mutant derived from the auxotrophic S. enterica var. Typhi strain 514Ty, was shown to be non-reactogenic in human volunteers given two oral doses of 5U10 10 cfu [58] . However, this candidate vaccine strain was poorly immunogenic. Therefore, in an attempt to provide a better compromise between virulence and immunogenicity, Hohmann et al. [44] constructed strain Ty800, a phoP phoQ mutant derived from S. enterica var. Typhi Ty2. In a dose escalation trial, this vaccine was shown to be safe and immunogenic [44] . Only volunteers receiving a dose of 1U10 10 cfu of Ty800 showed mild adverse e¡ects. Those receiving lower doses were not a¡ected and, importantly, no Ty800 was detected in blood cultures following vaccination [44] . S. enterica var. Typhi Ty2 cya crp cdt (strain M4073) has also yielded promising results in a recent trial [59] . Following inoculation with a single dose of up to 5U10 8 cfu of M4073, most healthy adult volunteers tolerated the vaccine well and developed S. enterica var. Typhi-speci¢c serum antibody responses and var. Typhi-speci¢c antibody-secreting cells. In comparison, disappointing results were obtained from a dose escalation trial in volunteers with S. enterica var. Typhi strain M8110, derived from wildtype strain ISP1820 [60] . This vaccine was insu⁄ciently immunogenic and vaccinaemias were noted. The live attenuated S. enterica var. Typhi strains CVD 908-htrA, Ty800 and M4073 are indeed promising candidate typhoid fever vaccines. Nevertheless, whilst these vaccines proceed through further clinical studies, there is a continued need to search for attenuated S. enterica var. Typhi strains as backup candidate vaccines if de¢ciencies are identi¢ed. Although CVD 908-htrA and Ty800 are thought to be safe, the question as to whether the strains are immunogenic enough remains to be answered. One potential alternative candidate vaccine strain recently developed is CVD 915, a guaBA deletion mutant of S. enterica var. Typhi Ty2 [46] . In the mouse model for typhoid, CVD 915 elicited S. enterica var. Typhi LPS-and £agella-speci¢c IgG at signi¢cantly higher levels compared to Ty21a, and similar levels to those elicited by CVD 908-htrA [46] . Phase I clinical trials will determine how well S. enterica var. Typhi CVD 915 is tolerated and how close it is to the optimum balance between low reactogenicity and adequate immunogenicity as a live typhoid vaccine.
Exploitation of S. enterica vaccines for the delivery of heterologous antigens
Since their development attenuated S. enterica strains have been well characterised in their use as carriers of heterologous antigens in the murine typhoid model. These strains are attractive for this use since they can be administered by the natural route of infection, i.e. orally, and are capable of eliciting both systemic and mucosal immune responses. Salmonella are also easily genetically manipulated and can express heterologous antigens from other pathogens, including those of both bacterial and eukaryotic origin. Furthermore, there are a number of advantages in using S. enterica var. Typhi to deliver heterologous antigens. First, such vaccines may be used in developing countries where typhoid fever and other diseases are prevalent. For example, Salmonella expression of tetanus toxin fragment C (TetC) may provide protection against tetanus, which remains a major cause of disease and death in developing countries. In addition, travellers receiving immunisation against typhoid fever may also be immunised against a number of diseases. In developed countries there is unlikely to be background immunity to S. enterica var. Typhi, so the use of the bacterium as a carrier is feasible. Various reviews have previously detailed examples of the use of Salmonella strains as carriers of heterologous antigens [61^64]. Many of these bivalent Salmonella vaccines have been shown to a¡ord protection against the pathogen from which the heterologous antigen is derived. These studies have allowed researchers to obtain an insight into the optimal construction of live attenuated S. enterica var. Typhi vaccines for use in humans.
A problem associated with the development of typhoid vaccines for use in humans over the years is that S. enterica var. Typhi is not known to be virulent in any animal model by the oral route of infection. However, a model of intranasal immunisation of mice has been developed in which the immunogenicity of attenuated S. enterica var. Typhi vaccines can be assessed. Using this model Galen et al. [65] were able to induce high titres of serum anti-tetanus toxin in mice immunised with CVD 908 expressing TetC, thus providing protection against tetanus toxin challenge. In comparison, dosing of mice with this vaccine strain via the orogastric route was ine¡ective. In recent years, the intranasal dosing model has been used to demonstrate the immunogenicity of bivalent S. enterica var. Typhi vaccine strains in a number of other studies [45,66^69] . For example, Wu et al. [69] demonstrated the induction of antibodies against the Plasmodium falciparum merozoite surface protein 1 (MSP-1) in mice immunised with CVD 908 expressing MSP-1 fused to TetC. Similarly, CVD 908 expressing the major surface protein gp63 of Leishmania mexicana mexicana was shown to be immunogenic, eliciting both humoral and cellular immune responses [67] .
Human clinical trials
To date a limited number of bivalent S. enterica var.
Typhi vaccines have been evaluated in clinical trials (Table  1) . In two volunteer studies, S. enterica var. Typhi M4073 expressing hepatitis B antigens (using the asd balancedlethal system) has been evaluated [59, 71] . In both studies the vaccine was poorly immunogenic against the heterologous antigen and, following oral inoculation, caused occasional febrile reactions. Similarly disappointing was the performance of S. enterica var. Typhi (Ty800) expressing Helicobacter pylori urease, which failed to induce ureasespeci¢c immunity in inoculated volunteers [72] . However, more promising results have been demonstrated in other studies. For example, in the ¢rst report of a human trial published, a vaccine based on strain CVD 908 was constructed in which a peptide of the circumsporozoite protein (CSP) of P. falciparum was expressed from the tac promoter [70] . The vaccine was well tolerated by volunteers given two doses of 5U10 7 cfu, 8 days apart, and three of 10 volunteers developed immune responses against CSP [70] . In another study, Tacket et al. [73] used CVD 908-htrA expressing TetC to immunise 21 adult volunteers in a dose escalation study. Three of nine volunteers who received 10 8 cfu or higher developed increased levels in serum antitoxin titres. Furthermore, the vaccine was shown to be capable of inducing protective levels of antitoxin [73] . It is not clear why some S. enterica var. Typhi-based vaccines have been able to induce detectable immune responses against carried antigens whilst others have not, but it is possible that some problems may arise as a result of unstable expression. Tacket et al. [73] , for example, plan to improve their CVD 908-htrA-based vaccine expressing TetC by incorporating a plasmid stabilisation system and a promoter that will delay expression of the antigen until the carrier is in vivo.
In an important volunteer study, the H. pylori urease was expressed from a S. enterica var. Typhimurium phoP phoQ strain [74] . In comparison to a previous clinical study in which S. enterica var. Typhi phoP phoQ expressing the urease had proven poorly immunogenic [72] , oral immunisation with the var. Typhimurium-based vaccine induced urease-speci¢c immune responses in three out of six volunteers [74] . Data from this study suggested that the improved immunogenicity of this vaccine may be due to a greater stability of antigen-expressing plasmid in the S. enterica var. Typhimurium carrier and/or prolonged intestinal colonisation [74] . The results from this study provide further clues to the way forward for the development of bivalent S. enterica var. Typhi vaccines for use in humans. In addition, this study provides the ¢rst report, to our knowledge, of S. enterica var. Typhimurium-based vaccines evaluated in humans.
However, one issue that remains to be fully understood is the e¡ect of prior immunity to Salmonella on the immune responses generated against carried antigens. To date a limited number of studies have been carried out [75^78] . An early report suggested that prior immunologic experience with a homologous serotype Salmonella strain does not have a deleterious e¡ect on the immunogenicity of carried antigens and, moreover, may be able to potentiate subsequent immune responses [75] . In comparison, more recent reports have shown that prior exposure to Salmonella may result in lower immune responses to heterologous antigens in Salmonella-immunised mice than in non-exposed mice [76^78] . Thus this issue requires further studies in order to understand the e¡ect of pre-existing immunity to Salmonella for the further use of Salmonella vaccines.
Development of recombinant S. enterica vaccines
Over the years, various problems in the development of Salmonella vaccines as vectors have arisen, resulting in reports of ine¡ective vaccines. However, advances in Salmonella vaccine vector technology in recent years have provided solutions to at least some of these problems.
Low-level or unstable expression of heterologous antigens
Expression of heterologous antigens at su⁄cient levels to elicit an immune response is a signi¢cant problem in the construction of heterologous Salmonella strains. If a vaccine is poorly immunogenic, the use of high-copy-number plasmids to increase recombinant antigen production can improve the immunogenicity [79^82]. Alternatively, the strategy of construction of tandem repeats of the heterologous antigen on the plasmid has been used [83^85].
Under some circumstances, however, high-level expression of a heterologous antigen has been found to be toxic to the Salmonella carrier. One possible solution is to construct expression cassettes in which promoters are located on inverting sequences, ensuring that heterologous antigen expression only occurs when the promoters are in frame with the antigen-encoding sequences [86^88]. An alternative strategy involves the use of promoters that allow expression of heterologous antigens at particular cellular sites, so-called in vivo-inducible promoters. Using these promoters, the level of antigen expression will be low until the Salmonella carrier recognises an environmental stimulus, which then results in increased antigen expression. Ideally, the promoters should allow increased expression in antigen-presenting cells (APCs) following uptake of the Salmonella carriers. One example is the nirB promoter, which is known to be induced in anaerobic environments [89] , and is induced by entry of the Salmonella into cells [90] . Expression of heterologous antigens in Salmonella from the nirB promoter has been shown to stimulate superior immune responses compared to similar strains that express the same antigens under the control of constitutive promoters [91^93] . The nirB promoter has also been used in the development of a number of other heterologous Salmonella vaccines [83,85,91,94^99]. Another anaerobi- [73] cally induced promoter, dmsA, has recently been used in S. typhi vaccine strain CVD 908-htrA for the controlled expression of TetC [100] . In the murine model, higher tetanus antitoxin titres were elicited by the vaccine compared to those elicited by a similar vaccine utilising the nirB promoter. The macrophage-inducible pagC promoter, controlled by the PhoP/PhoQ two-component regulatory system, has also been shown to provide stable, high-level expression of heterologous antigens in Salmonella [93, 98, 101, 102] . In addition, the stationary-phase inducible promoters, spv and dps, were shown to induce increased expression of a heterologous antigen, L-galactosidase, in Salmonella within macrophages [103] . Finally, other promoters used to date include the phoP and ompC promoters [102] , the htrA and groE promoters [90, 99, 104] , and the katG promoter [93] , all of which allow increased induction of heterologous antigen production in vivo.
Aside from the low-level expression of heterologous antigens in Salmonella, problems may be encountered regarding unstable expression of the antigens, particularly in vivo. Such problems may occur as a result of instability of the genes encoding the antigens. In early experiments, for example, a plasmid expressing the E. coli heat-labile enterotoxin subunit B was lost in vivo when the Salmonella carrier colonised the mouse RES [105] .
Studies have aimed to address the problem of genetic instability in di¡erent ways. Hone et al. [106] developed a system whereby DNA encoding a heterologous antigen could be integrated by recombination into the chromosome of a Salmonella carrier. First, a hisOG deletion was introduced into the chromosome of S. enterica serovar Typhimurium strain LT2H1 (galE). Then a suicide vector was constructed which carried the wild-type hisOG operon, heterologous DNA encoding E. coli K88 ¢mbriae, and £anking regions to allow incorporation of the operon into the Salmonella chromosome by homologous recombination. Clones in which integration of the wild-type his region and heterologous DNA had occurred were identi¢ed by selection of his þ bacteria [106] . This system has since been used to insert DNA encoding various heterologous antigens into the Salmonella chromosome [90,107^109] . One problem associated with this system, however, involves the levels of immune responses which may be elicited by immunisation with the resulting Salmonella vaccine strain. Using this system, antigen will be expressed from only a single copy of the foreign gene, compared to multiple copies of the gene present in Salmonella harbouring a multicopy expression plasmid. This may result in low expression of the antigen and, as a result, low immunogenicity. For example, Strugnell et al. [108] reported increased stability of the gene encoding TetC following insertion into the S. enterica var. Typhimurium chromosome, but the antigen expressed was not immunogenic. Therefore it is possible that several copies of the heterologous gene may need to be integrated into the Salmonella chromosome to obtain the desired e¡ects.
An alternative approach to genetic stability is the use of balanced-lethal plasmid stabilisation systems. This involves the insertion of the gene encoding the heterologous antigen into a plasmid containing a gene that complements a metabolic defect in the Salmonella carrier strain. A number of studies have utilised a system in which the asd gene is inactivated in Salmonella [47,59,71,110^112] . This gene encodes the enzyme aspartate L-semialdehyde dehydrogenase, required for the production of diaminopimelic acid, which is an essential component of bacterial peptidoglycan. In asd mutants of Salmonella the loss of the plasmid carrying the asd gene in vivo is lethal, therefore only Salmonella harbouring the plasmid survive. Using this system, cloning of heterologous antigens into an Asd þ expression vector allows stable expression of the antigen in vitro and in vivo. In another balanced-lethal system, an expression plasmid carrying the thymidylate synthetase (thyA) gene is used to complement a Salmonella vaccine strain with a thymidine requirement, caused by a mutation in the chromosomal thyA gene [113] . A novel example of a system for stabilisation of plasmids in Salmonella has recently been described by Galen et al. [114] . The approach is based on the naturally occurring hok-sok postsegregational killing system in which hok encodes a lethal pore-forming Hok protein, whose synthesis is blocked by hybridisation of antisense mRNA (called sok) to the hok mRNA. The Salmonella must maintain an expression plasmid carrying hok-sok in order to allow constitutive transcription which, in turn, maintains an intracellular environment which protects sok mRNA from degradation by nucleases. Salmonella which do not carry the plasmid are postsegregationally killed since levels of protected sok mRNA drop and levels of the more stable hok mRNA quickly lead to Hok synthesis and cell death. This plasmid stabilisation system has the advantage that plasmids stabilised by carrying hok-sok can be introduced into any live Salmonella vector strain without the requirement for additional genetic manipulation. However, the plasmid stabilisation e¡ect of this system was only temporary. Ultimately even bacteria which had lost the antigen-encoding plasmid were able to survive, possibly as a result of mutations spontaneously occurring in hok [114] . Plasmid stabilisation systems in Salmonella have been used with some success in human vaccine trials [71, 91, 115, 116] .
The instability associated with some heterologous antigens expressed by Salmonella carriers has been addressed by 'rescuing' these antigens through expression as chimeric fusions to the TetC. For example, the diphtheria toxin and S1 subunit of Bordetella pertussis toxin antigens were found to be susceptible to proteolytic degradation when expressed in the cytoplasm of Salmonella, but were rescued when fused to TetC [117, 118] . In other studies, it was found that the gp120 antigen of human immunode¢ciency virus-1 formed inclusion bodies when expressed in the Salmonella cytosol, but could be produced in a soluble form when the antigen was secreted [81, 119] .
Low immunogenicity
The magnitude and type of immune response induced against an expressed antigen may be in£uenced by a number of factors. For example, the cellular location of the expressed antigen has been considered such a factor for a number of years. This in£uence may be due to degradation of the antigen in certain cellular compartments or to a modi¢cation of antigen presentation to the immune system. Both antibody and cellular immune responses may be elicited against antigens that are expressed on the surfaces of carrier strains and, as a result, some researchers have focused on directing antigens that are normally expressed in the cytoplasm onto the cell surface. This has been carried out using signal sequences from exported proteins such as the periplasmic binding protein, MalE [120] . Alternatively, outer membrane proteins such as OmpA [121, 122] and LamB [120, 123] have been genetically fused to heterologous antigens to carry and relocate them in the Salmonella cell membrane. Since secreted antigens often induce immune responses during infection, it is thought that secretion of heterologous antigens from Salmonella carriers may also enhance their immunogenicity. Certainly, for two naturally secreted proteins, Hly (listeriolysin) and p60 of Listeria monocytogenes, secretion from Salmonella was shown to improve their immunogenicity [124] . These two protective antigens were expressed in S. enterica var. Typhimurium aroA in either secreted or cytoplasmically located forms. Vaccination of mice with Salmonella secreting Hly or p60 induced immunity that a¡orded protection against L. monocytogenes infection [124] . In comparison, Salmonella somatically displaying the antigens was insu⁄cient for induction of protective immunity. The same workers found that mice immunised with Salmonella secreting the naturally somatic antigen superoxide dismutase were also protected against L. monocytogenes challenge [125] . In recent years, secretion of heterologous antigens from Salmonella vaccine strains has also been achieved using the type III secretion system of Salmonella [126] or the E. coli Hly haemolysin secretion system [124, 127, 128] . Despite these studies, numerous studies have con¢rmed that induction of a broad spectrum of immune responses could be elicited against heterologous antigens expressed in the Salmonella cytoplasm. For example, an early study by Brown et al. [129] reported that both humoral and cellular immunity against cytoplasmically located L-galactosidase were induced. Thus it appears that cell surface expression is not a prerequisite for induction of both cellular and humoral immunity against heterologous antigens, although it is possible that some naturally secreted antigens may require cell surface expression in order to fold correctly and to adopt a conformation which is immunogenic.
The fusion of heterologous antigens to TetC for stabilisation purposes has been described above. However, fusion to proven carrier antigens, such as TetC, has also been shown to increase the immunogenicity of some antigens. For example, expression in Salmonella vaccine strains of the Schistosoma mansoni [94] or Schistosoma haematobium [130] 28-kDa glutathione S-transferases as fusions to TetC enhanced their immunogenicity. It is thought that TetC promotes the immune response against fused antigens by providing additional T cell helper epitopes [131] . In other studies, Streptococcus sobrinus antigens [132] or the E. coli heat-stable enterotoxin [133] were expressed in Salmonella as fusions to the E. coli heat-labile toxin subunit B (LT-B), which is also known to have immune-enhancing e¡ects. LT-B and CT-B, the cholera toxin B subunit, are well-known non-toxic adjuvants which contain structural features that provide adjuvant and immunogenic stimulation in the intestinal mucosa [134] . It may also be possible to modulate the immune response generated against heterologous antigens expressed by Salmonella by the co-expression or fusion to cytokines. To date, a number of cytokines have been expressed in Salmonella vaccine strains, some of which have been shown to have immunomodulatory e¡ects [135^142].
Use of selectable markers
The development of recombinant Salmonella vaccines has usually required the use of selectable markers, often conferring antibiotic resistance. However, it is feared that resistance genes may spread to pathogenic organisms in the environment, possibly rendering them refractory to antibiotic treatment. Since plasmids carrying antibiotic resistance genes may be unacceptable for human use, it has been necessary to develop Salmonella vaccine systems that do not contain antibiotic resistance markers. For example, the stable integration of heterologous antigens into the Salmonella chromosome can overcome the disadvantage of expressing antigens from recombinant plasmids which may require antibiotic selection for maintenance [109] . Alternatively, the plasmid maintenance systems described in Section 4.1 o¡er the opportunity to screen and select recombinant Salmonella without the need for antibiotic resistance markers [47, 114] . Another alternative is the thyA þ marker recently proposed for positive selection of recombinant Salmonella [143] .
Future perspectives
Delivery of DNA vaccines
DNA vaccination encompasses vaccination using naked DNA or DNA delivered by a carrier where the antigen is expressed under the control of a eukaryotic promoter. Such DNA vaccines show considerable potential for the induction of protective responses against some diseases [144] and some DNA vaccines are currently being evaluated in human clinical trials. However, e⁄cient delivery often requires the use of specialised equipment, such as gene gun-type technology for the intra-dermal delivery of DNA coated particles. Following vaccination, it is thought that primed APCs need to migrate to the spleen for the induction of immune responses [145] . It is desirable to deliver DNA vaccines directly to APCs, which can be achieved through the exploitation of attenuated intracellular bacteria.
A relatively recent development in the ¢eld of Salmonella vaccines involves their use as carriers of DNA vaccines. In 1995, it was ¢rst shown that live bacterial carriers could be used in this way [146] and, in 1997, a study by Darji et al. [147] reported the ¢rst use of S. enterica var. Typhimurium. An aroA strain was used to deliver DNA encoding two virulence factors of L. monocytogenes, ActA and listeriolysin, expressed under the control of the eukaryotic CMV promoter. When orally administered to BALB/c mice, multiple and even single immunisations induced substantial cellular and humoral immune responses against the antigens, and protective immunity was induced by listeriolysin transformants [147] . Since this initial study, there have been numerous reports of Salmonella-delivered DNA immunisation against bacteria and their toxins, viruses and tumour antigens ( Table 2) .
The mechanism by which Salmonella-delivered DNA vaccines are able to reach the appropriate cellular compartments for induction of immunity is unknown. Following infection and uptake by APCs, Salmonella resides in a specialised phagosome and it remains to be understood how the plasmid DNA is transported from the phagosomal compartment of the host cell into the nucleus for antigen expression. Catic et al. [153] attempted to determine the importance of cellular localisation of the Salmonella carrier in the delivery of DNA vaccines by studying the major histocompatibility complex (MHC) class I processing of a highly immunogenic hen egg ovalbumin peptide expressed from a eukaryotic expression plasmid delivered using a Salmonella strain. Speci¢cally, the e¡ects of using the haemolysin (Hly) system to enhance MHC class I processing were assessed. The Salmonella were able to gain access to the host cell cytosol by secretion of Hly, and to then deliver the plasmid encoding the ovalbumin peptide into the cytosol of macrophages in vitro. This phagosomal escape strategy was shown to enhance plasmid DNA delivery by Salmonella [153] . Subsequently, the same strategy was used for Salmonella delivery of a DNA vaccine encoding green £uorescent protein (GFP) [151] . Compared to controls, the additional expression of Hly increased the number of GFP-expressing peritoneal macrophages by two-to three-fold, suggesting that cytosolic delivery of DNA vaccines improves antigen expression in vivo [151] . These studies suggest that Salmonella strains with a phagosomal escape function, such as secreted Hly, are candidates for improved DNA vaccine delivery. In an alternative e¡ort to produce Salmonella strains for improved DNA vaccine delivery, Jain et al. [170] recently developed a system for the programmed lysis of the bacteria as a means of e⁄ciently release DNA vaccines into target cells. The S and R gene products of phage lambda, which cause bacterial lysis, were used to lyse S. enterica var. Typhimurium under the control of the arabinose-inducible promoter P BAD . This inducible lysis system is suitable for Salmonella release of DNA vaccines in vitro, and it will be interesting to see if such an approach may be applicable in vivo. It may also be possible to use in vivo inducible promoters to drive expression of lysis genes in Salmonella. For example, the actA promoter of L. monocytogenes was previously shown to drive expression of a lysis gene after invasion of host macrophages and subsequent entry into the cytosolic compartment. Lysis of the L. monocytogenes carrier was achieved, enabling release of the DNA [171] .
It has been demonstrated that Salmonella can be used for the delivery of DNA which is expressed in the eukaryotic cell and, as such, is a novel delivery system for oral administration of DNA vaccines. To date, however, there have been no reports of the trialling in humans of recombinant Salmonella for the delivery of DNA vaccines.
Concluding remarks
The future for Salmonella vaccines looks very promising. A number of well-tolerated attenuated S. enterica var. Typhi strains have been shown to be immunogenic in clinical trials. These are clearly promising candidate typhoid vaccines. In addition, Salmonella vaccines have been shown to protect against a broad range of pathogens in animal models and preliminary results from clinical trials demonstrate that protective immunity against heterologous antigens is achievable. In addition, Salmonella vaccines have been successfully used to induce antitumour immunity [138, 172, 173] . Various problems have been encountered, particularly in the development of bivalent Salmonella vaccines, but numerous solutions have been obtained already and other problems are likely to be addressed in a similar manner.
A signi¢cant development in the last few years involves the use of Salmonella vaccines for the delivery of DNA vaccines. Using bivalent Salmonella strains to deliver DNA vaccines may allow such vaccines to induce immunity against the Salmonella carrier, the heterologous antigen(s) expressed by the Salmonella, and the antigen(s) encoded by the DNA vaccine. Furthermore, it should be possible to simultaneously express heterologous antigens from the Salmonella chromosome and from plasmids carried by the Salmonella. It may even be possible to 'prime' and 'boost' within a single orally delivered immunisation, by delivering the DNA vaccine to the appropriate APCs for expression of antigen, and co-delivering an expressed antigen. This DNA vaccine delivery technology looks very promising to date, and o¡ers a new and exciting approach to mucosal vaccine delivery.
